Background
Methods
Setting
The Civil Registration System (CRS)
Danish HIV Cohort Study (DHCS)
Ethics
Study population
Definitions
Statistical analyses
Results
Time from eligibility to HAART initiation
Patient characteristics
Women | Men |
p-value
1
| |
---|---|---|---|
Subjects, n(%) | 473 (52.1) | 435 (47.9) | - |
Follow-up from initiation of HAART (years), median (IQR) | 5.9 (3.2-8.7) | 5.7 (2.7-8.5) | - |
Follow-up time from initiation of HAART, (person-years) | 2833 | 2519 | |
Age in years at HAART initiation, median (IQR) | 33.0 (28.6-40.1) | 43.2 (35.3-51.7) | <0.0001 |
Race, n(%) | |||
White | 137 (29.0) | 319 (73.7) | <0.0001 |
Asian | 76 (16.1) | 12 (2.8) | |
Black | 250 (53.0) | 90 (20.8) | |
Other | 9 (1.9) | 12 (2.8) | |
(missing) | (1) | (2) | |
Place of HIV transmission, n(%) | |||
Denmark | 127 (28.5) | 150 (38.3) | <0.0001 |
Europe + US | 19 (4.3) | 29 (7.4) | |
Africa | 224 (50.3) | 140 (35.7) | |
Asia | 72 (16.2) | 63 (16.1) | |
Other | 3 (0.7) | 10 (2.6) | |
(missing) | (28) | (43) | |
CD4 cell count at HAART initiation (cells/μl), median (IQR) | |||
All women included | 196 (90–290) | 180 (63–290) | 0.12 (0.026) |
Pregnant women excluded | 170 (80–270) | 180 (63–290) | 0,87 (0,21) |
HIV-RNA at HAART initiation (copies/mL), median (IQR) All women included | 50,800 (12,500-204,000) | 126,155 (32,200-501,000) | <0.0001 (0.0003) |
Pregnant women excluded | 61,320 (16,519-237,000) | 126,155 (32,200-501,000) | <0.0001 (0.0066) |
Acute HIV infection at HAART initiation, n(%) | 4 (0.9) | 15 (3.5) | 0.0089 |
AIDS before HAART initiation, n(%) All women included | 88 (18.6) | 106 (24.4) | 0.034 |
n(%) of all patients except pregnant women Pregnant women excluded | 87 (21.8) | 106 (24.4) | 0.37 |
Pregnant at HAART initiation, n(%) | 59 (12.5) | - | - |
Antiretroviral therapy before HAART, n(%) | 14 (3.0) | 12 (2.8) | 0.86 |
Hepatitis B co-infection2, n(%) | 30 (6.3) | 20 (4.6) | 0.25 |
Hepatitis C co-infection3, n(%) | 0 (0) | - | - |
First-line HAART 01.01.1997 – 31.12.2002 All women included | |||
3 NRTI’s4
| 21 (9.5) | 9 (4.3) | 0.29 |
2 NRTI’s + efavirenz | 71 (32.0) | 76 (35.9) | |
2 NRTI’s + nevirapine | 7 (3.2) | 6 (2.8) | |
2 NRTI’s + PI’s5
| 93 (41.9) | 94 (44.3) | |
Other regimen | 30 (13.5) | 27 (12.7) | |
Pregnant women excluded | |||
3 NRTI’s | 21 (11.1) | 9 (4.7) | 0.13 |
2 NRTI’s + efavirenz | 66 (37.7) | 76 (39.8) | |
2 NRTI’s + nevirapine | 5 (2.6) | 6 (3.1) | |
2 NRTI’s + PI’s | 73 (38.4) | 94 (44.3) | |
Other regimen | 25 (13.2) | 27 (12.7) | |
First-line HAART 01.01.2003 – 31.12.2009 All women included | |||
3 NRTI’s | 3 (1.2) | 1 (0.5) | <0.0001 |
2 NRTI’s + efavirenz | 150 (59.8) | 179 (80.3) | |
2 NRTI’s + nevirapine | 17 (6.8) | 13 (5.8) | |
2 NRTI’s + PI’s | 73 (29.1) | 20 (9.0) | |
Other regimen | 8 (3.2) | 10 (4.5) | |
Pregnant women excluded | |||
3 NRTI’s | 3 (1.4) | 1 (0.5) | 0.066 |
2 NRTI’s + efavirenz | 148 (70.5) | 179 (80.3) | |
2 NRTI’s + nevirapine | 15 (7.1) | 13 (5.8) | |
2 NRTI’s + PI’s | 36 (17.1) | 20 (9.0) | |
Other regimen | 8 (3.8) | 10 (4.5) |
Modification of HAART
Toxicity IR (95% CI) |
Other/UnknownIR (95% CI) | Toxicity IRR (95% CI) |
Other/UnknownIRR (95% CI) | |
---|---|---|---|---|
Adjusted for all listed confounders,
| ||||
Men | 0.52 (0.42-0.64) | 0.55 (0.44-0.68) | 1.00 | 1.00 |
Women | 0.49 (0.41-0.59) | 0.57 (0.48-0.67) | 0.97 (0.66-1.44) | 1.18 (0.76-1.85) |
Women (pregnant excluded) | 0.54 (0.45-0.66) | 0.49 (0.40-0.61) | 1.03 (0.69-1.52) | 1.14 (0.71-1.82) |
Incidence rates and incidence rate ratios for changes in HAART during the first year due to the following reasons: | Women IR 95%(CI) | Men IR 95%(CI) | Women vs. men (ref) unadjusted IRR 95%(CI) | Women vs. men (ref) adjusted IRR 95%(CI) |
---|---|---|---|---|
Toxicity, hypersensitivity | 0.09 (0.06-0.15) | 0.06 (0.03-0.14) | 1.43 (0.58-3.52) | −1
|
Toxicity, gastrointestinal | 0.22 (0.16-0.15) | 0.16 (0.10-0.26) | 1.37 (0.80-2.36) | 0.97 (0.49-1.93) |
Toxicity, neurological | 0.19 (0.13-0.27) | 0.20 (0.13-0.30) | 0.96 (0.56-1.64) | 1.48 (0.65-3.38) |
Toxicity, other | 0.18 (0.13-0.25) | 0.29 (0.21-0.40) | 0.62 (0.39-1.00) | −1
|